MNMD
Price
$12.51
Change
+$0.54 (+4.51%)
Updated
Oct 8, 12:40 PM (EDT)
Capitalization
910.77M
35 days until earnings call
VRDN
Price
$21.71
Change
+$0.72 (+3.43%)
Updated
Oct 8, 12:54 PM (EDT)
Capitalization
1.71B
41 days until earnings call
Interact to see
Advertisement

MNMD vs VRDN

Header iconMNMD vs VRDN Comparison
Open Charts MNMD vs VRDNBanner chart's image
Mind Medicine (MindMed)
Price$12.51
Change+$0.54 (+4.51%)
Volume$17K
Capitalization910.77M
Viridian Therapeutics
Price$21.71
Change+$0.72 (+3.43%)
Volume$2.57K
Capitalization1.71B
MNMD vs VRDN Comparison Chart in %
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MNMD vs. VRDN commentary
Oct 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNMD is a StrongBuy and VRDN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 08, 2025
Stock price -- (MNMD: $11.97 vs. VRDN: $21.00)
Brand notoriety: MNMD and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNMD: 116% vs. VRDN: 71%
Market capitalization -- MNMD: $910.77M vs. VRDN: $1.71B
MNMD [@Biotechnology] is valued at $910.77M. VRDN’s [@Biotechnology] market capitalization is $1.71B. The market cap for tickers in the [@Biotechnology] industry ranges from $105.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNMD’s FA Score shows that 0 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • MNMD’s FA Score: 0 green, 5 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, MNMD is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNMD’s TA Score shows that 5 TA indicator(s) are bullish while VRDN’s TA Score has 4 bullish TA indicator(s).

  • MNMD’s TA Score: 5 bullish, 4 bearish.
  • VRDN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, MNMD is a better buy in the short-term than VRDN.

Price Growth

MNMD (@Biotechnology) experienced а +1.53% price change this week, while VRDN (@Biotechnology) price change was -2.69% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.36%. For the same industry, the average monthly price growth was +18.20%, and the average quarterly price growth was +86.44%.

Reported Earning Dates

MNMD is expected to report earnings on Nov 12, 2025.

VRDN is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+8.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRDN($1.72B) has a higher market cap than MNMD($911M). MNMD YTD gains are higher at: 71.983 vs. VRDN (9.546). MNMD has higher annual earnings (EBITDA): -110.19M vs. VRDN (-340.62M). VRDN has more cash in the bank: 563M vs. MNMD (183M). VRDN has less debt than MNMD: VRDN (21.3M) vs MNMD (41.2M). VRDN has higher revenues than MNMD: VRDN (305K) vs MNMD (0).
MNMDVRDNMNMD / VRDN
Capitalization911M1.72B53%
EBITDA-110.19M-340.62M32%
Gain YTD71.9839.546754%
P/E RatioN/AN/A-
Revenue0305K-
Total Cash183M563M33%
Total Debt41.2M21.3M193%
FUNDAMENTALS RATINGS
MNMD vs VRDN: Fundamental Ratings
MNMD
VRDN
OUTLOOK RATING
1..100
7366
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
92
Overvalued
PROFIT vs RISK RATING
1..100
8978
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
3642
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
3990

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNMD's Valuation (36) in the null industry is somewhat better than the same rating for VRDN (92) in the Biotechnology industry. This means that MNMD’s stock grew somewhat faster than VRDN’s over the last 12 months.

VRDN's Profit vs Risk Rating (78) in the Biotechnology industry is in the same range as MNMD (89) in the null industry. This means that VRDN’s stock grew similarly to MNMD’s over the last 12 months.

MNMD's SMR Rating (98) in the null industry is in the same range as VRDN (99) in the Biotechnology industry. This means that MNMD’s stock grew similarly to VRDN’s over the last 12 months.

MNMD's Price Growth Rating (36) in the null industry is in the same range as VRDN (42) in the Biotechnology industry. This means that MNMD’s stock grew similarly to VRDN’s over the last 12 months.

MNMD's P/E Growth Rating (100) in the null industry is in the same range as VRDN (100) in the Biotechnology industry. This means that MNMD’s stock grew similarly to VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MNMDVRDN
RSI
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 10 days ago
84%
Bullish Trend 10 days ago
81%
Declines
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 7 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
80%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MIGYX66.31N/A
N/A
Invesco Main Street Y
MMIEX17.03N/A
N/A
MM S&P 500® Index Svc
AINIX17.96N/A
N/A
Ariel International Institutional
ARYVX13.81N/A
N/A
American Century Global Real Estate Inv
ILVBX11.01N/A
N/A
Columbia Integrated Large Cap Val A

MNMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNMD has been loosely correlated with ATAI. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if MNMD jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNMD
1D Price
Change %
MNMD100%
-2.05%
ATAI - MNMD
49%
Loosely correlated
+1.28%
RXRX - MNMD
49%
Loosely correlated
-5.42%
OCUL - MNMD
49%
Loosely correlated
+5.01%
SYRE - MNMD
48%
Loosely correlated
-3.90%
VRDN - MNMD
48%
Loosely correlated
+0.82%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with SYRE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
+0.82%
SYRE - VRDN
57%
Loosely correlated
-3.90%
NUVL - VRDN
56%
Loosely correlated
-0.56%
KRYS - VRDN
52%
Loosely correlated
+1.36%
CRNX - VRDN
52%
Loosely correlated
+1.97%
NRIX - VRDN
52%
Loosely correlated
-1.21%
More